Four large trials validating the benefits of indapamide, the guideline-endorsed antihypertensive diuretic

Jean-Jacques Mourad MD, PhD, FESC, Chef de Service de Medicine Interne recently expressed, “What a nice way to start the year being associated with my prestigious colleagues Giuseppe Mancia and John Chalmers on this publication that merged data from 4 major trials including unpublished outcomes from the Progress trial”

This new publication was made by the Journal of Hypertension January 13, 2023 with the aim to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug in randomized controlled trials (RCTs).

Aggregate data from four published RCTs conducted versus matching placebo were pooled: PATS, a 2-year study (indapamide), and PROGRESS, a 4-year study (indapamide and perindopril), both in patients with a history of stroke or transient ischemic attack; ADVANCE, a 4-year study in patients with type 2 diabetes and cardiovascular risk factor (single-pill combination perindopril/indapamide) and HYVET, a 2-year study in very elderly hypertensive individuals (indapamide and an option of perindopril).

Statistically significant risk reductions in the indapamide with or without perindopril-treated patients as compared to placebo were observed for all-cause death (−15%), cardiovascular death (−21%), fatal stroke (−36%) and all strokes (−27%). Other cardiovascular outcomes were improved (risk reduction, 22 to 36%)

Click here

SCAC 01/23 DM 025 SERVIER-For the exclusive use of the health care professional